AB0723 SMOKING MAY BE RELATED TO SACROILIITIS IN ENTEROPATHIC ARTHRITIS PATIENTS: TREASURE REAL-LIFE PRELIMINARY DATA. (June 2019)

• Record Type: Journal Article
• Authors: Küçükşahin, Orhan; Erden, Abdulsamet; İlgen, Ufuk; Kiraz, Sedat; Ertenli, Ali İhsan; Yasar Bilge, Nazife Sule; Kaşifoğlu, Timuçin; Dalkılıç, Ediz; Bes, Cemal; Kanıtez, Nilüfer alpay; Emmungil, Hakan; Atagündüz, Pamir; Seniz, Belkis Nihan; Yağız, Burcu; Koca, Süleyman Serdar; Çınar, Muhammet; Ateş, Aşkın; Akar, Servet; Gerçik, Önay; Ersözlü, Duygu; Yazısız, Veli; Kimyon, Gezmiş; Aydın, Müge; Mercan, Rıdvan; Öz, Burak; Akar, Zeynel abidin; Karadag, Omer; Keleşoğlu, Bahar; Yılmaz, Sedat; Pehlivan, Yavuz; Terzioğlu, Ender; Kılıç, Levent; Erten, Sukran; Taşçılar, Koray; Kalyoncu, Umut;
• Is Part Of: Annals of the rheumatic diseases. Volume 78(2019)Supplement 2
• Page Start: 1824
• Page End: 1825
• Publication Date: 2019-06
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2019-eular.5888
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Articular manifestations may differ in ulcerative colitis (UC) and Crohn's disease (CD). Genetic and non-genetic factors like sex, smoking, and presence of HLA-B27 were previously shown to modify the expression of articular and other extraintestinal manifestations of IBD. Objectives: The aim of this study is to document disease features and factors affecting the expression of articular manifestations in Turkish patients with IBD-related (enteropathic) arthritis under treatment with disease modifying antirheumatic drugs (DMARDs). Methods: Data regarding enteropathic arthritis (EA) were collected from the TReasure database, a nation-wide multicenter observational registry of inflammatory arthritis patients. Results: Among 4066 patients with seronegative spondyloarthropaties (SpA), 156 (3.8%) had EA, not reflecting a true prevalence due to selection bias. Demographic and clinical features according to IBD groups were summarized in Table 1 . Rates of presence of sacroiliitis were similar between patients with UC and CD (39.9% and 60.1%, p=0.086 respectively). Rates of HLA-B27 positivity were 31.6% and 7.1% in patients with and without radiographic sacroiliitis, respectively (p=0.101). Enthesitis, dactylitis, psoriasis, family history forSpA, ESR, CRP, BASDAI and aSDAS levels had similar distributions in patients with and without radiographic sacroiliitis. Rates of "never-smoked" (26.5% vs 64.7%) and "current smoking" (32.4% vs 17.6%) significantly differed in patients with and without sacroiliitis (overall p=0.012) Conclusion: Our data confirm an association between smoking status and disease manifestations, particularly radiographic sacroiliitis. References: [1] Fries W. Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J Gastroenterol2009; 15: 2449-2455. Disclosure of interests: Orhan Küçükşahin: None declared, abdulsamet Erden: None declared, Ufuk İlgen: None declared, Sedat Kiraz: None declared, ali İhsan Ertenli: None declared, Nazife Sule Yasar Bilge: None declared, Timuçin Kaşifoğlu: None declared, Ediz Dalkılıç Grant/research support from: MSD and abbvie, Consultant for: MSD, abbvie, Roche, UCB, Pfizer and Novartis, Speakers bureau: MSD, abbvie, Roche, UCB, Pfizer and Novartis, Cemal Bes: None declared, Nilüfer alpay Kanıtez: None declared, Hakan Emmungil Grant/research support from: MSD, Roche, Pfizer, abbvie, Consultant for: Novartis, Roche, Speakers bureau: MSD, Roche, Pfizer, abbvie, Celltrion, Novartis, Pamir atagündüz: None declared, Belkis Nihan Seniz: None declared, Burcu Yağız: None declared, Süleyman Serdar Koca: None declared, Muhammet Çınar: None declared, aşkın ateş: None declared, Servet akar Grant/research support from: MSD, abbvie, Roche, UCB, Novartis, Pfizer, amgen, Consultant for: MSD, abbvie, Roche, UCB, Novartis, Pfizer, amgen, Speakers bureau: Pfizer, Önay Gerçik: None declared, Duygu Ersözlü: None declared, Veli yazısız: None declared, Gezmiş Kimyon: None declared, Müge aydın: None declared, Rıdvan Mercan: None declared, Burak Öz: None declared, Zeynel abidin akar: None declared, Omer Karadag: None declared, Bahar Keleşoğlu: None declared, Sedat Yılmaz: None declared, Yavuz Pehlivan: None declared, Ender Terzioğlu: None declared, Levent Kılıç: None declared, Sukran Erten: None declared, Koray Taşçılar: None declared, Umut Kalyoncu Grant/research support from: MSD, Roche, UCB, Novartis and Pfizer, Consultant for: MSD, abbvie, Roche, UCB, Novartis, Pfizer and abdi Ibrahim, Speakers bureau: MSD, abbvie, Roche, UCB, Novartis, Pfizer and abdi Ibrahim